Startups

Science Corporation's brain implant venture reaches $3.5B valuation on PRIMA expansion

Max Hodak's neurotechnology startup raised $400M Series D to advance vision-restoration implants and bio-hybrid brain sensors.

Last verified:

Series D Fuels Dual-Track Neurotechnology Strategy

Science Corporation, the medical-device startup founded by former Neuralink president Max Hodak in 2021, has closed a $400 million Series D at a $3.5 billion post-money valuation, according to TechCrunch. According to the company’s announcement, the round was led by Khosla Ventures alongside Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. The capital will accelerate FDA commercialization of its current vision implant while funding early-stage trials of an ambitious bio-hybrid brain interface.

PRIMA Implant Clears European Approval, Pursues US Pathway

Science’s near-term product, PRIMA, is an implantable chip addressing age-related macular degeneration—a leading cause of vision loss in older populations. According to TechCrunch, the device has received regulatory approval in Europe and is currently available in Germany. The company recently announced an expansion into Stargardt’s disease, a separate blindness-causing condition, with patient trials now underway.

To bring PRIMA to US patients, Science Corporation is pursuing the FDA’s Humanitarian Device Exemption (HDE) pathway, a regulatory track designed for experimental therapies addressing rare conditions. According to the reporting, the company has persuaded the agency that advanced macular degeneration affecting both eyes qualifies as sufficiently uncommon to merit HDE designation—a narrower and faster approval route than standard premarket clearance.

Bio-Hybrid Brain Sensor Enters Human Trial Design Phase

Hodak’s founding vision extends beyond vision restoration. According to TechCrunch, Science is developing a bio-hybrid sensor combining cultured neurons and silicon architecture for direct brain interfacing. Yale neurosurgery professor Murat Günel is currently designing the initial human trials of this device, which could address Parkinson’s disease and other neurological injuries and illnesses, Günel told TechCrunch.

This dual architecture—a revenue-generating implant near commercialization paired with early-stage research into invasive brain-computer interfaces—mirrors the broader neurotechnology industry’s pattern of funding ambitious long-term programs through near-term medical products.

Why This Matters

The $3.5B valuation reflects investor confidence that implantable neurotechnology can achieve regulatory approval and commercial scale in Western markets. For teams evaluating neurotech-adjacent opportunities, Science Corporation’s HDE strategy offers a template: win regulatory clarity on a narrowly defined patient population, establish clinical reimbursement, then leverage that revenue base to fund riskier, longer-horizon research. The involvement of Tenet Healthcare—a major hospital network operator—signals that distribution and clinical integration, not just device engineering, are now financed components of the venture thesis.

Frequently Asked Questions

What is PRIMA and how does it work?

PRIMA is a wearable and implantable chip designed to help people with age-related macular degeneration recover partial vision. It is currently approved in Europe and available in Germany.

What is Science Corporation's longer-term goal beyond PRIMA?

The company aims to build a bio-hybrid brain sensor combining cultured neurons and silicon for direct brain interfacing, with potential applications in Parkinson's disease and other neurological conditions.

Who is leading the human trials for the brain sensor?

Yale neurosurgery professor Murat Günel is designing the initial human trials of the bio-hybrid device with Science Corporation.

#neurotech #medical-devices #brain-computer-interface #funding #implants